Contribute Try STAT+ Today

Aetna wants an employee to return or destroy documents that formed the basis of a whistleblower lawsuit she filed against CVS Caremark, alleging that the pharmacy benefit manager improperly reported generic drug prices to the federal government, according to a source familiar with the matter.

At the same time, CVS Caremark is seeking to redact key portions of the lawsuit, which is currently under seal, before it is made available to the public (although you can read it here). The lawsuit, which STAT first reported last month, revolves around the complicated contracts between pharmacy benefit managers and Medicare Part D plans, as well as the pricing that must be reported to the Centers for Medicare and Medicaid Services.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Go back more than 10 years and research how CVS was the preferred pharmacy for Blue Cross Blue Shield of RI.

  • Quite a spot to be in – serving the interests of the old master only to be sold to a new one, where such things conflict. Bad analogy, perhaps, but I find it thought provoking.

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy